SAID JACOB: Open Payments
NPI 1528128949 · GLENDORA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$197,592 in 438 payments from 16 companies in 2025. Trend: 2023 $206,351 · 2024 $190,936 · 2025 $197,592
Speaker / faculty: $153,677Consulting: $26,212Food & beverage: $11,341Travel & lodging: $6,362
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 92 | $72,656 |
| Neurocrine BioSciences, Inc. | 88 | $47,801 |
| Otsuka America Pharmaceutical, Inc. | 56 | $32,245 |
| Alkermes, Inc. | 51 | $21,476 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 38 | $13,951 |
| ABBVIE INC. | 34 | $5,187 |
| E.R. Squibb & Sons, L.L.C. | 21 | $1,961 |
| Axsome Therapeutics, Inc. | 17 | $944 |
| Vanda Pharmaceuticals Inc. | 21 | $651 |
| Alpha Cognition USA, Inc. | 7 | $303 |
Products named: INGREZZA, AUSTEDO XR, REXULTI, UZEDY, LYBALVI, CAPLYTA, VRAYLAR, ABILIFY MAINTENA.
Industry payments across CA — which companies pay providers there.
